Short report: Absence of an association between Plasmodium falciparum infection and post-ivermectin Loa-related non-neurologic serious adverse events

American Journal of Tropical Medicine and Hygiene

Volumn 90, Issue 2, 2014, Pages 335-338

  Fokom Domgue, Joël ^a,b   Pion, Sébastien D ^b,e   Gounoue, Raceline ^b   Akame, Julie ^b,c   Nguipdop Djomo, Patrick ^a,b   Twum Danso, Nana A Y ^b,d   Thylefors, Björn ^b,d   Boussinesq, Michel ^b,e   Kamgno, Joseph ^a,b  

^a Filariasis and Other Tropical Diseases Research Centre   (Cameroon)

^b UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^c HELEN KELLER INTERNATIONAL   (United States)

^d Mectizan Donation Program   (United States)

^e INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IVERMECTIN;

ADULT; AGED; ARTICLE; BLOOD SMEAR; CAMEROON; DISEASE ASSOCIATION; DRUG FEVER; DRUG INDUCED HEADACHE; FEMALE; HUMAN; LOA LOA; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MANSONELLA PERSTANS; MANSONELLIASIS; MIDDLE AGED; MIXED INFECTION; PARASITE LOAD; PLASMODIUM FALCIPARUM; RISK FACTOR; TROPHOZOITE; YOUNG ADULT; ANIMAL; DRUG EFFECT; ISOLATION AND PURIFICATION; LOA; LOIASIS; MALARIA; MANSONELLA; MULTIVARIATE ANALYSIS; STATISTICAL MODEL;

ADULT; ANIMALS; COINFECTION; FEMALE; HUMANS; IVERMECTIN; LOA; LOGISTIC MODELS; LOIASIS; MALARIA; MALE; MANSONELLA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMODIUM FALCIPARUM; RISK FACTORS;

EID: 84893459511     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.13-0189     Document Type: Article

References (8)

1. Zouré HGM, Wanji S, Noma M, Amazigo UV, Diggle PJ, Tekle AH, Remme JHF, 2011. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the rapid assessment procedure for loiasis (RAPLOA). PLoS Negl Trop Dis 5: e1210.
2. Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux J-P, 2003. Clinical picture, epidemiology and outcome of Loaassociated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J 2 (Suppl 1): S4.
3. Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M, 1997. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 350: 18-22.
4. Kamgno J, Pion SD, Mackenzie CD, Thylefors B, Boussinesq M, 2009. Loa loa microfilarial periodicity in ivermectin-treated patients: comparison between those developing and those free of serious adverse events. Am J Trop Med Hyg 81: 1056-1061.
5. Bourguinat C, Kamgno J, Boussinesq M, Mackenzie CD, Prichard RK, Geary TG, 2010. Analysis of themdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a postivermectin serious adverse event. Am J Trop Med Hyg 83: 28-32.
6. White V, Lewallen S, Beare N, Molyneux M, Taylor T, 2009. Retinal pathology of pediatric cerebral malaria in Malawi. PLoS One 4: e4317.
7. Kamgno J, Boussinesq M, Labrousse F, Nkegoum B, Thylefors BI, Mackenzie CD, 2008. Encephalopathy after ivermectin treatment in a patient infected with Loa loa and Plasmodium spp. Am J Trop Med Hyg 78: 546-551. (Pubitemid 351845154)
8. Twum-Danso NAY, 2003. Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases. Filaria J 2 (Suppl 1): S3.